Compare PRIM & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRIM | APGE |
|---|---|---|
| Founded | 1960 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.7B |
| IPO Year | 2006 | 2023 |
| Metric | PRIM | APGE |
|---|---|---|
| Price | $86.65 | $133.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 13 |
| Target Price | ★ $155.20 | $109.67 |
| AVG Volume (30 Days) | 1.9M | ★ 5.4M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.19% | N/A |
| EPS Growth | ★ 51.66 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.92 | N/A |
| Revenue Next Year | $8.80 | N/A |
| P/E Ratio | $275.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $65.00 | $34.34 |
| 52 Week High | $205.50 | $134.32 |
| Indicator | PRIM | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 39.92 | 80.60 |
| Support Level | $65.00 | $80.52 |
| Resistance Level | $99.29 | N/A |
| Average True Range (ATR) | 3.99 | 0.42 |
| MACD | 0.90 | -1.40 |
| Stochastic Oscillator | 14.13 | 80.12 |
Primoris Services Corp is a provider of critical infrastructure services operating mainly in the United States and Canada. The company provides a range of construction, maintenance, replacement, and engineering services. The Utilities segment operates throughout the United States and specializes in a range of services, including the construction and maintenance of new and existing natural gas and electric utility distribution and transmission systems, and communications systems. The Energy segment operates throughout the United States and Canada and specializes in a range of services that include engineering, procurement, construction, and maintenance services to various industries. The majority of the company's revenue is derived from the Energy segment.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.